ArticleFrontiers in immunology2026
Risk factors for cutaneous immune-related adverse events: a systematic scoping review.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To comprehensively summarize risk factors and explore potential mechanisms associated with cutaneous immune-related adverse events (cirAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs). Method: Conducted in accordance with the PRISMA-ScR guidelines, this review included studies published in English and Chinese that investigated cirAEs risk factors in cancer patients receiving ICIs. A scoping review with systematic search criteria was conducted using PubMed, Embase, Cochrane, Web of Science, ProQuest, CINAHL, CNKI, Wanfang Data, VIP, and SinoMed from database inception to December to December 31, 2023. Results: 4905 studies were identified and 50 studies were included in this review, encompassing 198,514 participants. Among these, 12.5% experienced at least one cirAEs, with maculopapular rash, pruritus, and unspecified rash being the most common subtypes. A total of 68 distinct risk factors were identified from these studies, categorized into three primary risk domains: demographic factors, clinical characteristics, and biomarkers, including age, gender, BMI, smoking history, specific treatment regimens (e.g., camrelizumab), tumor type (e.g., melanoma), eosinophil count, and cytokine levels, among others. The odds ratios (OR) for reported risk factors demonstrated significant associations with specific cirAEs subtypes, with melanoma patients exhibiting higher risk for multiple cirAEs subtypes. However, there was significant variability in the quality of reporting for these risk factors, emphasizing the need for improved consistency and accuracy in data reporting. Conclusions: A variety of demographic, clinical, and biomarker-related factors contribute to the development of cirAEs. Characterizing these risk factors can address clinical needs for cirAE identification, while further mechanistic studies are needed to enhance management strategies. However, there is a limited amount of high-quality prospective evidence on these risk factors, and the quality of reporting on immunotherapy-related adverse events is inconsistent. Future research should focus on validating clinically valuable risk factors and interrogating mechanisms underlying cirAEs emergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.